The global Geographic Atrophy Market is expected to witness substantial growth over the forecast period from 2025 to 2034, fueled by a rising elderly population, increasing disease prevalence, growing demand for disease-modifying treatments, and the advancement of novel therapeutic approaches—particularly complement inhibitor therapies, according to DelveInsight.
The evolving GA treatment landscape is being reshaped by a strong pipeline of emerging therapies, including Gildeuretinol (Alkeus Pharmaceuticals), Tinlarebant (Belite Bio), AVD-104 (Aviceda Therapeutics), JNJ-1887 (Johnson & Johnson Innovative Medicine), OGX-110 (Ocugenix), OCU410 (Ocugen), BI 1584862 (Boehringer Ingelheim), and several others currently in clinical development.
👉Discover in-depth Geographic Atrophy market insights, pipeline analysis, and revenue forecasts through 2034—access DelveInsight’s comprehensive Geographic Atrophy Market Report today: https://www.delveinsight.com/sample-request/geographic-atrophy-ga-market
Geographic Atrophy Market Overview
DelveInsight’s Geographic Atrophy Market Insights report delivers an in-depth analysis of current treatment paradigms, late-stage and emerging therapies, competitive dynamics, and market size forecasts from 2020 to 2034 across major markets, including the United States, EU4 (Germany, France, Italy, Spain), the United Kingdom, and Japan.
Key highlights include:
- The geographic atrophy treatment market is projected to grow steadily across all major markets through 2034.
- The United States represents the largest share of the global GA market.
- Approximately 700,000 prevalent GA cases were reported in the U.S. in 2024.
- Leading companies such as Alkeus Pharmaceuticals, Belite Bio, Roche, AstraZeneca, Annexon Biosciences, Apellis Pharmaceuticals, Iveric Bio, Ionis Pharmaceuticals, and others are actively advancing innovative GA therapies.
Growth Drivers Shaping the Geographic Atrophy Market
Rising Disease Prevalence
The increasing incidence of geographic atrophy, an advanced form of age-related macular degeneration (AMD) is closely linked to global aging trends and longer life expectancy.
Advances in Diagnostic Technologies
Improved imaging tools, including spectral-domain OCT and fundus autofluorescence, are enabling earlier and more accurate disease detection and progression monitoring.
Regulatory and Clinical Milestones
Annexon Biosciences’ ANX007 became the first GA therapy to receive PRIME designation in the EU, highlighting its potential to address major unmet needs.
Emerging Cell and Gene Therapies
Encouraging data from RPE cell-based therapies such as CPCB-RPE1 and OpRegen support regenerative approaches as viable treatment strategies.
Launch of Novel Therapies
Multiple oral, injectable, gene, and cell therapies targeting complement pathways, visual cycle modulation, mitochondrial function, and retinal regeneration—are expected to significantly alter the Geographic Atrophy treatment landscape.
👉Stay ahead in the evolving Geographic Atrophy landscape by exploring late-stage drug pipelines, complement inhibitor therapies, and upcoming approvals shaping the @ Geographic Atrophy market
Geographic Atrophy Market Landscape and Therapeutic Trends
Complement pathway inhibitors currently represent the most advanced and only approved drug class for Geographic Atrophy. FDA approvals of SYFOVRE (pegcetacoplan) and IZERVAY (avacincaptad pegol) marked a major breakthrough in GA treatment.
Although early safety concerns temporarily slowed SYFOVRE’s adoption, strong Q4 sales performance indicates sustained market momentum. With additional therapies anticipated to seek regulatory approval between 2025 and 2027, competition is expected to intensify.
Given the elderly GA patient population, therapies offering less frequent dosing or one-time administration may achieve higher adoption rates, positioning them as future standards of care.
Geographic Atrophy Competitive Landscape Highlights
Notable therapies in clinical development include:
- Gildeuretinol (ALK-001) – oral, once-daily vitamin A analog
- Tinlarebant – oral visual cycle modulator (Phase III PHOENIX trial)
- OGX-110 – CXCR3-targeting regenerative therapy
- ANX007, NGM621, Danicopan, IONIS-FB-LRx, CPCB-RPE1, and others
These candidates represent diverse mechanisms of action aimed at slowing disease progression and preserving visual function.
Geographic Atrophy Market Recent Developments
- November 2025: Apellis reported five-year GALE extension data supporting long-term SYFOVRE efficacy
- October 2025: Astellas released extended Phase III data for IZERVAY showing sustained lesion growth reduction
- July 2025: Belite Bio completed enrollment in its pivotal Phase III Tinlarebant trial
- October 2025: FDA approved IND for Complement Therapeutics’ gene therapy candidate CTx001
Key Geographic Atrophy Market Companies
Leading Geographic Atrophy companies such as
- Alkeus Pharmaceuticals,Â
- Belite Bio,Â
- Roche,Â
- AstraZeneca,Â
- Annexon Biosciences,Â
- Apellis Pharmaceuticals,Â
- Iveric Bio,Â
- Ionis Pharmaceuticals, and others
Geographic Atrophy Market Outlook
With a growing patient base, significant unmet needs, and a rapidly expanding therapeutic pipeline, the geographic atrophy market is entering a transformative phase. Emerging disease-modifying therapies are expected to redefine treatment standards, unlock commercial opportunities, and substantially improve patient outcomes over the next decade.
👉Unlock actionable insights into Geographic Atrophy drug development, clinical trial progress, and future standards of care with DelveInsight’s expert-driven @ Geographic Atrophy analysis.
Geographic Atrophy Report Metrics
| Study Period | 2020–2034 |
| Geographic Atrophy Market Report Coverage | 7MM [The United States, the EU-4 (Germany, France, Italy, and Spain), the United Kingdom, and Japan] |
| Geographic Atrophy Epidemiology Segmentation | Total Prevalent Cases of AMD, Late Stage-specific Prevalent Cases of AMD, Total Prevalent Cases of Geographic Atrophy, Total Diagnosed Prevalent Cases of Geographic Atrophy, Age-specific Cases of Geographic Atrophy, Geographic Atrophy Cases by Visual Impairment, and Total Treated Cases of Geographic Atrophy |
| Key Geographic Atrophy Companies | Alkeus Pharmaceuticals, Belite Bio, Aviceda Therapeutics, Johnson & Johnson Innovative Medicine, Ocugenix, Ocugen, Boehringer Ingelheim, Lineage Cell Therapeutics (CellCure Neurosciences), Roche, Cognition Therapeutics, Stealth BioTherapeutics, Evergreen Therapeutics, Annexon Biosciences, NGM Biopharmaceuticals, AstraZeneca, Alexion Pharmaceuticals, Ionis Pharmaceuticals, Regenerative Patch Technologies, Astellas Pharma, Iveric Bio, Apellis Pharmaceuticals, and others |
| Key Geographic Atrophy Therapies | Gildeuretinol, Tinlarebant, AVD-104, JNJ-1887, OGX-110, OCU410, BI 1584862, OpRegen, CT1812, Elamipretide, EG-301, ANX007, NGM621, Danicopan (ALXN2040), IONIS-FB-LRx, CPCB-RPE1, IZERVAY, SYFOVRE, and others |
